RNA (Avidity Biosciences) EPS (Basic) : $-2.89 (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences EPS (Basic)?

Avidity Biosciences's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.65. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.89.

Avidity Biosciences's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.65. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.89.

Avidity Biosciences's EPS without NRI for the three months ended in Sep. 2024 was $-0.65. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -2.89.

During the past 3 years, the average EPS without NRI Growth Rate was -12.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -40.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Avidity Biosciences's highest 3-Year average EPS without NRI Growth Rate was -12.40% per year. The lowest was -73.90% per year. And the median was -40.90% per year.

Avidity Biosciences EPS (Basic) Historical Data

The historical data trend for Avidity Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences EPS (Basic) Chart

Avidity Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.20

-2.05

-2.85

-3.34

-2.91

Avidity Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.71	-0.80	-0.79	-0.65	-0.65

Avidity Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Avidity Biosciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-212.22	-	0)	/	73.012
	=	-2.91

Avidity Biosciences's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-80.398	-	0)	/	123.375
	=	-0.65

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89

Avidity Biosciences (NAS:RNA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Avidity Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Avidity Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121

Website

https://www.aviditybiosciences.com

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Executives

Arthur A Levin	officer: Chief Scientific Officer	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Teresa Mccarthy	officer: Chief Human Resources Officer	10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Michael F Maclean	officer: Chief Financial Officer	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
W. Michael Flanagan	officer: Chief Technical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Sarah Boyce	director, officer: President and CEO	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker	director	C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim	officer: Chief Medical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	director, 10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Roderick Wong	director, 10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014